Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

This study has been completed.
National Cancer Institute (NCI)
Information provided by:
Memorial Sloan Kettering Cancer Center Identifier:
First received: September 6, 2002
Last updated: June 4, 2013
Last verified: June 2013

RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Combining interferon alfa with imatinib mesylate may kill more cancer cells.

PURPOSE: Phase II trial to study the effectiveness of combining interferon alfa with imatinib mesylate in treating patients who have chronic myelogenous leukemia.

Condition Intervention Phase
Biological: recombinant interferon alfa
Drug: imatinib mesylate
Phase 2

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Open Label Study to Determine Safety and Efficacy of Interferon-alpha in Combination With Imantinib Mesylate (Gleevec) in Patients With Chronic Phase Chronic Myelogenous Leukemia Who Have Not Achieved a Complete Cytogenetic Response to Gleevec as a Single Agent

Resource links provided by NLM:

Further study details as provided by Memorial Sloan Kettering Cancer Center:

Study Start Date: April 2002
Study Completion Date: October 2003
Primary Completion Date: October 2003 (Final data collection date for primary outcome measure)
Detailed Description:


  • Determine whether interferon alfa in combination with imatinib mesylate adds to the hematologic, cytogenetic, and molecular response rates in patients with chronic phase chronic myelogenous leukemia that is newly diagnosed or has not achieved a complete cytogenetic response to imatinib mesylate alone.

OUTLINE: Patients receive oral imatinib mesylate (STI-571) once daily for 9 months. At 9 months, patients with more than 35% Philadelphia chromosome-positive (Ph+) cells in bone marrow receive oral STI-571 twice daily for 3 more months. At 12 months, patients with more than 35% Ph+ cells in bone marrow receive oral STI-571 once daily and interferon alfa subcutaneously once daily. Treatment continues for at least 1 year in the absence of disease progression or unacceptable toxicity. Patients with an appropriate HLA-matched donor may choose to have a bone marrow transplantation at any time during the study.

Patients are followed every 6 months for 3 years.

PROJECTED ACCRUAL: A total of 80 patients (60 without an HLA-matched donor and 20 with an HLA-matched donor) will be accrued for this study within 5 years.


Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Diagnosis of chronic phase chronic myelogenous leukemia

    • Cytogenetically confirmed Philadelphia chromosome-positive disease or other variant of t(9;22)

      • No secondary chromosomal abnormalities
    • No more than 10% blasts in bone marrow
    • Newly diagnosed OR
    • Received prior imatinib mesylate as a single agent for no more than the past 9 months without achieving a complete cytogenetic response
  • No evidence of extramedullary involvement except nodes, liver, or spleen



  • Any age

Performance status

  • ECOG 0-3

Life expectancy

  • Not specified


  • Platelet count greater than 100,000/mm^3
  • Absolute neutrophil count greater than 1,500/mm^3


  • Bilirubin no greater than 2 times upper limit of normal (ULN)
  • SGOT no greater than 2 times ULN
  • INR no greater than 1.5 times ULN*
  • PTT no greater than 1.5 times ULN* NOTE: * Except patients on anticoagulants


  • Creatinine no greater than 2 times ULN


  • Considered potentially reliable
  • No history of noncompliance to medical regimens
  • No other active malignancy requiring chemotherapy or radiotherapy
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective barrier-method contraception during and for at least 3 months after study


Biologic therapy

  • No prior interferon therapy
  • No prior stem cell or bone marrow transplantation


  • No prior chemotherapy (except hydroxyurea and/or anagrelide to control counts)

Endocrine therapy

  • Not specified


  • Not specified


  • At least 4 weeks since prior major surgery and recovered


  • No concurrent grapefruit juice or grapefruit products
  • No concurrent warfarin
  • Concurrent low-molecular weight heparin allowed
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00045422

United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10021
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Study Chair: Ellin Berman, MD Memorial Sloan Kettering Cancer Center
  More Information

Additional Information:
No publications provided Identifier: NCT00045422     History of Changes
Other Study ID Numbers: 02-013, CDR0000256469, NCI-G02-2105
Study First Received: September 6, 2002
Last Updated: June 4, 2013
Health Authority: United States: Federal Government

Keywords provided by Memorial Sloan Kettering Cancer Center:
chronic myelogenous leukemia, BCR-ABL1 positive
chronic phase chronic myelogenous leukemia
childhood chronic myelogenous leukemia

Additional relevant MeSH terms:
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid
Leukemia, Myeloid, Chronic-Phase
Bone Marrow Diseases
Hematologic Diseases
Myeloproliferative Disorders
Neoplasms by Histologic Type
Anti-Infective Agents
Antineoplastic Agents
Antiviral Agents
Enzyme Inhibitors
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protein Kinase Inhibitors
Therapeutic Uses processed this record on November 25, 2015